Outsourcing

Articles

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Ajinomoto Althea Adds High Potency Capabilities

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Innovation speeds discovery, drives down costs, and improves productivity.

Top Trends in Biopharmaceutical Manufacturing, 2017

CDMO Micro-Sphere is investing CHF 21 million (approximately $21.63 million) into the expansion of its GMP manufacturing capabilities at its Swiss facility.

Swiss CDMO Expands GMP Manufacturing Capabilities

Gil Roth is president of the Pharma & Biopharma OutsourcingAssociation, gil.roth@pharma-bio.org.

Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.

CDMOs: New Administration, New Frontier

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

CMOs must embrace flexibility in their technology decisions and business arrangements.

CMOs Must Embrace Flexible Manufacturing

Catalent expands the scope of the OptiForm Solution Suite to bridge gap from late-stage discovery to Phase I trials.


Catalent Adds Early Development Offerings to OptiForm Platform

Pfizer’s new format of ibuprofen (AdvilR Liqui-GelsR Minis) uses Catalent’s softgel technology to deliver the formulation in a more concentrated fill, resulting in smaller capsules.

Pfizer Picks Catalent to Manufacture Newly Launched Pain-Relief Product

Recro Gainsville expands its tableting capacity with the addition of a tablet press and film coater.

Recro Gainesville Adds Manufacturing Capacity

Samsung BioLogics signs $55.5 million agreement to manufacture tildrakizumab for Sun Pharma.

Samsung BioLogics to Manufacture Tildrakizumab

Matthew Moorcroft is vice-president, global marketing for Cambrex.

As pharma models changed during the past 40 years, contract manufacturing capacity and services evolved to meet demand.

Contract Manufacturing Services